Apr 29, 2021
        – Study did not meet Primary Endpoint of worst-itch NRS change from baseline at         week 12 or Secondary Endpoint of 4-point responder analysis in the ITT patient population         – Study achieved Primary Endpoint of worst-itch NRS change and Secondary Endpoint of 4-point responder
Additional Formats
Mar 08, 2021
FDA has set Prescription Drug User Fee Act (PDUFA) target action date of August 23, 2021 If approved, KORSUVA™ injection would be first therapy for treatment of pruritus in hemodialysis patients STAMFORD, Conn , and ST. GALLEN , Switzerland , March 08, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics
Additional Formats
Contact IR
email alerts